Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFIRMELLE vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Prevention of pregnancy (FDA-approved)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
~99% bound to serum albumin and sex hormone-binding globulin.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Oral: ~70% due to first-pass metabolism.
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
None.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Do not use in pregnancy. No dose recommendations available; contraindicated.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFIRMELLE vs ANDEMBRY, answered by our medical review team.
AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFIRMELLE and ANDEMBRY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFIRMELLE and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.